On September 14 afternoon, Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ, stock price 56.45 yuan, market value 632.19 billion yuan) announced that the company recently received a "Notice Letter on Share Reduction" from Shen Ping, a person acting in concert with controlling shareholder Wang Junmin. The notice disclosed that Shen Ping reduced her holdings of company shares by 1.25 million shares through centralized bidding transactions from September 1 to September 12, 2025, representing 0.11% of the company's total share capital. It is understood that Shen Ping and Wang Junmin are married.
After this equity change, the combined holdings of Shen Ping and Wang Junmin decreased from 449 million shares to 448 million shares, with their combined shareholding ratio declining from 40.11% to 40.00%. The post-change ratio touched the integer multiples of 1% and 5%. It was noted that Haisco Pharmaceutical's stock price just reached a historical high in August this year.
Meanwhile, Haisco Pharmaceutical continues to advance its private placement initiative. In July this year, the company announced that the Shenzhen Stock Exchange had accepted its application for issuing shares to specific targets, with plans to issue no more than 70 million shares and raise total funds not exceeding 1.365 billion yuan.
The announcement shows that before this equity change, Shen Ping held 4.43% of Haisco Pharmaceutical's total share capital, with her shareholding ratio decreasing to 4.32% after the reduction. Wang Junmin's shareholding remained unchanged. Their combined shareholding decreased from 449 million shares to 448 million shares, with the combined ratio dropping from 40.11% to 40.00%.
Haisco Pharmaceutical stated in its announcement that shareholder Shen Ping's share reduction was due to personal funding needs. As of the signing date of this equity change report, the two parties do not rule out the possibility of equity changes within the next 12 months.
It was observed that this is not the first recent reduction by persons acting in concert with Haisco Pharmaceutical's controlling shareholder.
In January this year, Haisco Pharmaceutical announced that from December last year to January this year, Shen Ping and Hao Congmei (spouse of former controlling shareholder Zheng Wei, who has terminated the concerted action relationship with Wang Junmin) reduced their holdings by 6.08 million shares and 1.52 million shares respectively, with reduction price ranges of 31.14-39.60 yuan per share and 31.60-35.72 yuan per share respectively.
In July, Haisco Pharmaceutical announced again that Shen Ping planned to reduce company shares by no more than 10.3734 million shares within three months starting 15 trading days after the announcement disclosure, representing no more than 0.926% of the company's total share capital. In the September 14 announcement, Haisco Pharmaceutical stated that after this equity change, Shen Ping's reduction plan has not been fully implemented.
It was noted that Haisco Pharmaceutical's stock price recently reached new highs. On August 13, Haisco Pharmaceutical's closing price was 60.24 yuan per share, up more than 80% from the beginning of the year (January 2). On September 15, the company's closing price was 56.45 yuan per share, with a market value reaching 632 billion yuan.
On the other hand, while persons acting in concert with the controlling shareholder have made multiple reductions, Haisco Pharmaceutical is also actively advancing its private placement.
In July this year, Haisco Pharmaceutical announced that the Shenzhen Stock Exchange had accepted its application for issuing shares to specific targets. This private placement plan was disclosed on February 28 this year, planning to issue no more than 70 million shares and raise total funds not exceeding 1.365 billion yuan, of which approximately 965 million yuan will be used for new drug R&D projects and 400 million yuan for supplementing working capital.
Prior to this, Haisco Pharmaceutical completed an 800 million yuan financing round in 2023.
In the first half of this year, Haisco Pharmaceutical achieved operating revenue of 2.0 billion yuan, up 18.63% year-on-year; net profit attributable to shareholders was 129 million yuan, down 21.79% year-on-year; non-GAAP net profit attributable to shareholders was 145 million yuan, up 90.84% year-on-year.
Among these, the core product Ciprofol Injection made the main contribution, achieving sales of approximately 800 million yuan, up 55% year-on-year. As of the interim report disclosure date, Haisco Pharmaceutical had 17 Class 1 innovative drug products in clinical stages, with total R&D expenses of 342 million yuan for the period.
On September 15 afternoon, attempts to reach Haisco Pharmaceutical's public phone line were unsuccessful.
Comments